

P.O. Box 418 Hamilton, Ohio 45012+0418

100 Riverfront Plaza Hamilton, Ohio 45011 513 * 867 * 6400

Fairfield 3000 Mack Road Fairfield, Ohio 45014 5:3 x 870 x 7000

03/10/97

Materials Licensing Section United States Nuclear Regulatory Commission Region III 801 Warrenville Road Lisle, Illinois 60532-43512

Please add the following physicians to our license #34-13663-01 for the use of any byproduct material identified in 10 CFR 35.400. They are all on staff at Christ Hospital, Cincinnati, Ohio and their license number is 34-03831-02

Peter Fried Rodney Geier Jennifer Gerson Ralph Wright

Also, enclosed is a copy of our revised Quality Management Program.

Thank you,

Margo A. Bartheld, CNMT Nuclear Medicine Department

large & But I

A MEMBER OF

MERCY

200029

9705200268 970310 PDR ADDCK 03002859 PDR

Pm: 4-1-97

RECEIVED APR 0 4 1997 REGION III

030-02859

NRC FORM 374

八重八重八重八重八重八重八重八重八重八重八重八重八重八重八重

U.S. NUCLEAR REGULATORY COMMISSION

第八章八章八章八章八章八章八章八章八章八章八章八章八章 OF . Amendment No. 48

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and sepresentations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. The Christ Hospital	In accordance with letter dated November 3, 1995 3. License Number 34-03831-02 is amended in its entirety to read as follows:
2. 2139 Auburn Avenue Cincinnati, OH 45219	4. Expiration Date December 31, 1995
	5. Docket or Reference No. 030-02725
Byproduct, Source, and/or Speciai Nuclear Material	7. Chemical and/or Physical 8. Maximum Amount that Licensee May Possess at Any One Time Under This License
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical A. As needed identified in 10 CFR 35.100
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical B. As needed identified in 10 CFR 35.200
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical C. As needed identified in 10 CFR 35.300
O. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy source D. As needed identified in 10 CFR 35.400
E. Any byproduct material identified in 10 CFR 35.500	E. Sealed sources identified E. As needed in 10 CFR 35.500
F. Carbon-14	F. Any F. 15 millicuries
G. Hydrogen-3	G. Any G. 240 millicuries
H. Iodine-125	H. Any H. 80 millicuries
I. Phosphorus-32	I. Any I. 50 millicuries
J. Phosphorus-33	J. Any J. 50 millicuries

9602010203 951207 03002725 PDR

ALL PARTY OF THE P	TATATATATATATATATATATATATA	AND THE PROPERTY OF THE PROPER	THE RESERVE OF THE PERSON NAMED IN COLUMN TWO IS NOT THE OWNER, THE PERSON NAMED IN COLUMN TWO IS NOT THE OWNER, THE OWNE			
MATERIALS LICENS SUPPLEMENTARY SHE		EAR REGULATORY COMMISSION	License number	PAGE 2 OF 4 PAGES		
		CENSE	ALLEGATIVE ALMANDES	34-03831-02		
			Docket or Reference number 030-02725			
			Amen	dment No. 48		
6.	Byproduct, source, and/or special nuclear material	7. Chemical and/ physical form		8. Maximum amount that licensee may possess at any one time under this license		
K.	Sulfur-35	K. Any		K. 40 millicuries		
L.	Selenium-75	LANZ REC	3//	L. 3 millicuries		
М.	Cesium-137	Operations Mo or New Englan Model NER-570	(Technical del 77307 d Nuclear	M. 165 millicuries		
N.	Chromium-51	N. Any		N. 50 millicuries		
9.	Authorized Use:					
Α.	Medical use described in 1	0 CFR 35.100.				
8.	Medical use described in 1	O CFR 35.200.				
С.	Medical use described in 1	0 CFR 35.300.				
D.	Medical use described in 1	0 CFR 35.400.				
Ε.	. Medical use described in 10 CFR 35.500 in devices which have been evaluated and approved for licensing purposes by the U.S. Nuclear Regulatory Commission or an Agreement State.					
F.	through L. In vitro studies.					
М.	For use in Technical Operations Model 773 calibrator to calibrate the licensee's survey meters.					
N.	In vitro and animal studie	S.				
-		221122222				

CONDITIONS

- Location of Use: 2139 Auburn Avenue, Cincinnati Ohio, and 4747 Lake Forrest Drive, Cincinnati, Ohio.
- 11. Radiation Safety Officer: Clifford C. Born, M.S.



License number

PAGES

MATERIALS LICENSE SUPPLEMENTARY SHEET

34-03831-02 Docket or Reference number 030-02725

Amendment No. 48

12. Authorized Users:

- A. Sumantha Ploysongsang, M.D., for material in 10 CFR 35.400 and 35.500.
- B. Kathryn Ann Weichert, M.D., for material in 10 CFR 35.400.
- C. Bernard S. Aron, M.D., for material in 10 CFR 35.400.
- Pearl J. Compaan, M.D., for material in 10 CFR/35.400. D.
- E. Harry Horwitz, M.D., for material in 10 CFR 35.400.
- F. Richard Levy, M.D., for material in 10 CFR 35.400.
- Thomas M. Morand, M.D., for material in 10 CFR 35.400. G.
- Kenneth E. Murdock, M.D., for material in 10 CFR 35.400. H.
- Harold T. Pretorius, M.D., for material in 10 CFR 35.100, 35.200, Ι. 35.300, 35.500, and in vitro studies.
- Rodney P. Geier, M.D., for material in 10 CFR 35.400 and phosphorus-32 J. as colloidal chromic phosphate for treatment of malignant effusions.
- Stephen J. Pomeranz, M.D., for material in 10 CFR 35.100, 35.200, K. 35.300, 35.500, and in vitro studies.
- Richard L. Ward, Ph.D., for in vitro studies and animal studies. L.
- M. Ann B. Bjornson, Ph.D., for in vitro studies and animal studies.
- Clifford G. Born, M.S., for in vitro studies and animal studies. N.
- 0. Ralph Jay Wright III, M.D., for material in 10 CFR 35.400 and phosphorus-32 as colloidal chromic phosphate for treatment of malignant effusions.
- John Breneman, M.D., for material in 10 CFR 35.400 and phosphorus-32 as P. colloidal chromic phosphate for treatment of malignant effusions.
- 0. Peter Fried, M.D., for material in 10 CFR 35.300 and 35.400.
- R. Parshan Singh Ram-Singh, M.D., for material in 10 CFR 35.100, 35.200, 35.300, 35.500 and in vitro studies.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License number 34-03831-02 Docket or Reference number 030-02725

Amendment No. 48

12. Authorized Users (Continued)

- Gregg N. Milligan, Ph.D., for in vitro studies. S.
- Bahige M. Baroudy, Ph.D., for in vitro studies. Τ.
- U. Kevin Redmond, M.D., for material in 10 CFR 35.400 and phosphorus-32 as colloidal chromic phosphate for treatment of malignant effusions.
- ٧. William L. Barret, M.D., for material in 10 CFR 35.400 and phosphorus-32 as colloidal chromic phosphate for treatment of malignant effusions.
- Jennifer Gerson, M.D., for material in 10 CFR 35.400.
- Χ. Richard Rolfes, M.D., for material in 10 CFR 35.100, 35.200, 35.300, 35.500 and in-vitro studies.
- Robert B. Summe, M.D., for material in 10 CFR 35.400.
- Pursuant to Title 10, Chapter 1, Code of Federal Regulations, Part 40, "Domestic Licensing of Source Material," the licensee is authorized to possess, use, transfer, and import up to 999 kilograms of depleted uranium contained as shielding material in the molybdenum-99/technetium-99 generators authorized by this license.
- The licensee shall maintain records of information important to safe and effective decommissioning at 2139 Auburn Avenue, Cincinnati Ohio, per the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.
- Notwithstanding the provisions of 10 CFR 34.400(d), the licensee may use Iridium-192 seeds encased in nylon ribbon as described in letter dated July 20, 1992, for intracavitary treatment of cancer.
- This license is based on the licensee's statements and representations listed below:
 - Application dated June 25, 1990; and
 - Letters dated August 23, 1990, September 27, 1990, July 7, 1995 (excluding all reference to Robert B. Summe, M.D.) and November 3, 1995 (with enclosed close-out survey data for licensee facility located at 2141 Auburn Avenue).

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date Rumber 7, 1995

Licensing Branch,